Pharmacokinetics and Pharmacodynamics of SM-20302, a GPIIb/IIIa Receptor Antagonist, in Anesthetized Dogs
Authors:
- Jinbao HuangJHJinbao Huang
- Wayne J. ShiuWSWayne J. Shiu
- Kumi SaitoKSKumi Saito
- Munekiyo KanekoMKMunekiyo Kaneko
- Yoshikazu SaitohYSYoshikazu Saitoh
- Benedict R. LucchesiBLBenedict R. Lucchesi
- 1 September 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 32 (3) , 485-494
Abstract
We examined the pharmacokinetic and pharmacodynamic properties of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. SM-20302 was administered intravenously in doses of 30 (n = 2), 100 (n = 4), 300 (n = 4), and 1,000 μg/kg (n = 4). The half-life of the initial phase was 4 min, and that of the terminal phase was 162-209 min. SM-20302 produced a dose-dependent increase in the initial plasma concentration and the area under concentration-time curve but did not alter the volume of distribution, mean residence time, or plasma clearance. Plasma clearance for SM-20302 ranged from 6.58 to 9.73 ml/min/kg. All doses of SM-20302 inhibited (≥90%) the ex vivo platelet aggregation induced by adenosine diphosphate (ADP) or arachidonic acid (AA) in citrated platelet-rich plasma (cPRP). In heparinized PRP (hPRP), a dose-dependent (44-89%) inhibition was observed. By using a sigmoid Emax model, the in vivo median inhibitory concentration (IC50) for SM-20302 was estimated to be 14-19 ng/ml in cPRP and 79-89 ng/ml in hPRP. To validate the calculated parameters, an infusion regimen was designed for the prevention of coronary artery thrombosis. Infusion of SM-20302 produced 64-67% inhibition of platelets in hPRP and maintained vessel patency despite vessel wall injury. The results suggest that SM-20302 exhibits linear pharmacokinetics and that its ability to inhibit platelet aggregation in hPRP may correlate more accurately with its in vivo antithrombotic efficacy.Keywords
This publication has 34 references indexed in Scilit:
- Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosisBlood Coagulation & Fibrinolysis, 1996
- Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptorsJACC, 1995
- Pharmacokinetics and Pharmacodynamics of TP-9201, a GPIIbIIIa Antagonist, in Rats and DogsJournal of Cardiovascular Pharmacology, 1995
- Myocardial neutrophil infiltration, lipid peroxidation, and antioxidant activity after coronary artery thrombosis and thrombolysisAmerican Heart Journal, 1995
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Toward the quiescent coronary plaqueJACC, 1993
- Clopidogrel, A Novel Antiplatelet and Antithrombotic AgentCardiovascular Drug Reviews, 1993
- Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.Journal of Clinical Investigation, 1990
- Platelet Membrane Glycoprotein IIb/IIIa: Member of a Family of Arg-Gly-Asp—Specific Adhesion ReceptorsScience, 1986
- Peritonitis in rats: RNA content of mononuclear cells in exudate and influence of dexamethasone and actinomycin D treatment on itInflammation Research, 1984